생체재료학회지 (Biomaterials Research)

  • 제22권4호
  • /
  • Pages.221-234
  • /
  • 2018
  • /
  • 1226-4601(pISSN)
  • /
  • 2055-7124(eISSN)
한국생체재료학회 (Korean Society for Biomaterials)
권호 표지
DOI QR코드

DOI QR Code

Mitochondria-targeting theranostics

  • Kang, Han Chang (Department of Pharmacy, College of Pharmacy, The Catholic University of Korea)
  • 투고 : 2018.08.21
  • 심사 : 2018.10.08
  • 발행 : 2018.12.31
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Interest in subcellular organelle-targeting theranostics is substantially increasing due to the significance of subcellular organelle-targeting drug delivery for maximizing therapeutic effects and minimizing side effects, as well as the significance of theranostics for delivering therapeutics at the correct locations and doses for diseases throughout diagnosis. Among organelles, mitochondria have received substantial attention due to their significant controlling functions in cells. Main body: With the necessity of subcellular organelle-targeting drug delivery and theranostics, examples of mitochondria-targeting moieties and types of mitochondria-targeting theranostics were introduced. In addition, the current studies of mitochondria-targeting theranostic chemicals, chemical conjugates, and nanosystems were summarized. Conclusion: With the current issues of mitochondria-targeting theranostic chemicals, chemical conjugates, and nanosystems, their potentials and alternatives are discussed.

키워드

과제정보

연구 과제 주관 기관 : National Research Foundation of Korea (NRF)

참고문헌

  1. Weissig V, Pettinger TK, Murdock N. Nanopharmaceuticals (part 1): products on the market. Int J Nanomedicine. 2014;9:4357-73.
  2. Rajendran L, Knolker HJ, Simons K. Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov. 2010;9:29-42. https://doi.org/10.1038/nrd2897
  3. Mossalam M, Dixon AS, Lim CS. Controlling subcellular delivery to optimize therapeutic effect. Ther Deliv. 2010;1:169-93. https://doi.org/10.4155/tde.10.8
  4. Smith RA, et al. Mitochondrial pharmacology. Trends Pharmacol Sci. 2012;33:341-52. https://doi.org/10.1016/j.tips.2012.03.010
  5. Szewczyk A, Wojtczak L. Mitochondria as a pharmacological target. Pharmacol Rev. 2002;54:101-27. https://doi.org/10.1124/pr.54.1.101
  6. Yamada Y, Harashima H. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv Drug Deliv Rev. 2008;60:1439-62. https://doi.org/10.1016/j.addr.2008.04.016
  7. Battogtokh G, et al. Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectives. Acta Pharmaceutica Sinica B. 2018. https://doi.org/10.1016/j.apsb.2018.05.006.
  8. Michaelis L. Die vitale Farbung, eine Darstellungsmethode der Zellgranula. Arch Mikrosk Anat. 1899;55:558-75. https://doi.org/10.1007/BF02977747
  9. Liberman EA, et al. Mechanism of coupling of oxidative phosphorylation and the membrane potential of mitochondria. Nature. 1969;222:1076. https://doi.org/10.1038/2221076a0
  10. Weiss MJ, et al. Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation. Proc Natl Acad Sci. 1987;84:5444-8. https://doi.org/10.1073/pnas.84.15.5444
  11. Burns RJ, Smith RAJ, Murphy MP. Synthesis and characterization of Thiobutyltriphenylphosphonium bromide, a novel thiol reagent targeted to the mitochondrial matrix. Arch Biochem Biophys. 1995;322:60-8. https://doi.org/10.1006/abbi.1995.1436
  12. Weissig V, et al. DQAsomes: a novel potential drug and gene delivery system made from $Dequalinium^{TM}$. Pharm Res. 1998;15:334-7. https://doi.org/10.1023/A:1011991307631
  13. Wu S, et al. Design, synthesis and biological evaluation of mitochondria targeting theranostic agents. Chem Commun (Camb). 2014;50:8919-22. https://doi.org/10.1039/C4CC03296A
  14. Guo D, et al. Cell-permeable iminocoumarine-based fluorescent dyes for mitochondria. Org Lett. 2011;13:2884-7. https://doi.org/10.1021/ol200908r
  15. Xu S, et al. Probing the anticancer action of Oridonin with fluorescent analogues: visualizing subcellular localization to mitochondria. J Med Chem. 2016;59:5022-34. https://doi.org/10.1021/acs.jmedchem.6b00408
  16. Fantin VR, et al. A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell. 2002;2:29-42. https://doi.org/10.1016/S1535-6108(02)00082-X
  17. Wang J, et al. Conjugated 5-fluorouracil with mitochondria-targeting lipophilic cation: design, synthesis and biological evaluation. MedChemComm. 2016;7:2016-9. https://doi.org/10.1039/C6MD00268D
  18. He H, et al. A novel bifunctional mitochondria-targeted anticancer agent with high selectivity for cancer cells. Sci Rep. 2015;5:13543. https://doi.org/10.1038/srep13543
  19. MacDonald IJ, et al. Subcellular localization patterns and their relationship to photodynamic activity of pyropheophorbide-a derivatives. Photochem Photobiol. 1999;70:789-97. https://doi.org/10.1111/j.1751-1097.1999.tb08284.x
  20. Liu L, Zhang Z, Xing D. Cell death via mitochondrial apoptotic pathway due to activation of Bax by lysosomal photodamage. Free Radic Biol Med. 2011;51:53-68. https://doi.org/10.1016/j.freeradbiomed.2011.03.042
  21. Teiten MH, et al. Endoplasmic reticulum and Golgi apparatus are the preferential sites of Foscan localisation in cultured tumour cells. Br J Cancer. 2003;88:146-52. https://doi.org/10.1038/sj.bjc.6600664
  22. Tang PM, et al. Pheophorbide a, an active compound isolated from Scutellaria barbata, possesses photodynamic activities by inducing apoptosis in human hepatocellular carcinoma. Cancer Biol Ther. 2006;5:1111-6. https://doi.org/10.4161/cbt.5.9.2950
  23. Choi BH, et al. The sensitivity of cancer cells to pheophorbide a-based photodynamic therapy is enhanced by Nrf2 silencing. PLoS One. 2014;9:e107158. https://doi.org/10.1371/journal.pone.0107158
  24. Cho H, et al. Bioreducible branched polyethyleneimine derivatives physically loaded with hydrophobic pheophorbide a: preparation, characterization, and light-induced cytotoxicity. Macromol Biosci. 2014;14:1483-94. https://doi.org/10.1002/mabi.201400145
  25. Kim WL, et al. Biarmed poly(ethylene glycol)-(pheophorbide a)2 conjugate as a bioactivatable delivery carrier for photodynamic therapy. Biomacromolecules. 2014;15:2224-34. https://doi.org/10.1021/bm5003619
  26. Kim CS, et al. Inactivation of mitochondrial electron transport by photosensitization of a pheophorbide a derivative. Mol Cells. 2004;17:347-52.
  27. Rapozzi V, et al. Conjugated PDT drug: photosensitizing activity and tissue distribution of PEGylated pheophorbide a. Cancer Biol Ther. 2010;10:471-82. https://doi.org/10.4161/cbt.10.5.12536
  28. Kwon S, et al. Mitochondria-targeting indolizino[3,2-c]quinolines as novel class of photosensitizers for photodynamic anticancer activity. Eur J Med Chem. 2018;148:116-27. https://doi.org/10.1016/j.ejmech.2018.02.016
  29. Tan X, et al. Structure-guided design and synthesis of a mitochondriatargeting near-infrared fluorophore with multimodal therapeutic activities. Adv Mater. 2017;29. Article No. 1704196.
  30. Jiang M, et al. A simple mitochondrial targeting AIEgen for image-guided twophoton excited photodynamic therapy. J Mater Chem B. 2018;6:2557-65. https://doi.org/10.1039/C7TB02609A
  31. Taba F, et al. Mitochondria-targeting polyamine-Protoporphyrin conjugates for photodynamic therapy. ChemMedChem. 2018;13:15-9. https://doi.org/10.1002/cmdc.201700467
  32. Hammerer F, et al. Mitochondria-targeted cationic porphyrin-triphenylamine hybrids for enhanced two-photon photodynamic therapy. Bioorg Med Chem. 2018;26:107-18. https://doi.org/10.1016/j.bmc.2017.11.024
  33. Feng G, et al. Artemisinin and AIEgen conjugate for mitochondria-targeted and image-guided chemo- and photodynamic Cancer cell ablation. ACS Appl Mater Interfaces. 2018;10:11546-53. https://doi.org/10.1021/acsami.8b01960
  34. Noh I, et al. Enhanced photodynamic Cancer treatment by mitochondriatargeting and brominated near-infrared fluorophores. Advanced Science. 2018;5:1700481. https://doi.org/10.1002/advs.201700481
  35. Hu M, et al. A hypoxia-specific and mitochondria-targeted anticancer theranostic agent with high selectivity for cancer cells. J Mater Chem B. 2018;6:2413-6. https://doi.org/10.1039/C8TB00546J
  36. Lee JH, et al. Self-assembled Coumarin nanoparticle in aqueous solution as selective mitochondrial-targeting drug delivery system. ACS Appl Mater Interfaces. 2018;10:3380-91. https://doi.org/10.1021/acsami.7b17711
  37. Choi YS, et al. Photosensitizer-mediated mitochondria-targeting nanosized drug carriers: subcellular targeting, therapeutic, and imaging potentials. Int J Pharm. 2017;520:195-206. https://doi.org/10.1016/j.ijpharm.2017.02.013
  38. Wang S, et al. Dual-mode imaging guided multifunctional Theranosomes with mitochondria targeting for Photothermally controlled and enhanced photodynamic therapy in vitro and in vivo. Mol Pharm. 2018;15:3318-31. https://doi.org/10.1021/acs.molpharmaceut.8b00351
  39. Palao-Suay R, et al. Photothermal and photodynamic activity of polymeric nanoparticles based on alpha-tocopheryl succinate-RAFT block copolymers conjugated to IR-780. Acta Biomater. 2017;57:70-84. https://doi.org/10.1016/j.actbio.2017.05.028
  40. Zhang X, et al. Multimodal Upconversion Nanoplatform with a mitochondria-targeted property for improved photodynamic therapy of Cancer cells. Inorg Chem. 2016;55:3872-80. https://doi.org/10.1021/acs.inorgchem.6b00020
  41. Hua XW, et al. Carbon quantum dots with intrinsic mitochondrial targeting ability for mitochondria-based theranostics. Nanoscale. 2017;9:10948-60. https://doi.org/10.1039/C7NR03658B
  42. Xu J, et al. Preparation of a mitochondria-targeted and NO-releasing nanoplatform and its enhanced pro-apoptotic effect on cancer cells. Small. 2014;10:3750-60. https://doi.org/10.1002/smll.201400437
  43. Guo R, et al. Mitochondria-targeting magnetic composite nanoparticles for enhanced phototherapy of Cancer. Small. 2016;12:4541-52. https://doi.org/10.1002/smll.201601094
  44. Ma Z, et al. Fe(III) -doped two-dimensional C3 N4 Nanofusiform: a new O2-evolving and mitochondria-targeting photodynamic agent for MRI and enhanced antitumor therapy. Small. 2016;12:5477-87. https://doi.org/10.1002/smll.201601681

피인용 문헌

  1. Mitochondrial and Nuclear DNA Oxidative Damage in Physiological and Pathological Aging vol.39, pp.8, 2018, https://doi.org/10.1089/dna.2019.5347
  2. Mitochondria-Targeted Self-Assembly of Peptide-Based Nanomaterials vol.9, pp.None, 2018, https://doi.org/10.3389/fbioe.2021.782234
  3. Mitochondria targeted fluorogenic theranostic agents for cancer therapy vol.452, pp.None, 2022, https://doi.org/10.1016/j.ccr.2021.214283